Astria Therapeutics, Inc. (ATXS) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 13, 2024 4:10 PM EST-- Navenibart (STAR-0215), the Potential Market-Leading Therapy for the Treatment of Hereditary Angioedema, on Track for Expected Phase 3 Initiation in Q1 2025 --
-- Final 3- and 6-Month Results from the ALPHA-STAR Trial of Navenibart Expected in Q4 2024 --
-- STAR-0310 Investigational New Drug (IND) Application Submission On-Track for Year-End 2024 --
-- Phase 1a Trial of STAR-0310 in Healthy Subjects Expected to Initiate in Q1 2025 --
BOSTON--(BUSINESS... More
